Treatment of neurodegenerative diseases through inhibiton of hsp90

Abstract

Treatment of neurodegenerative diseases is achieved using small molecule purine scaffold compounds that inhibit Hsp90 and that possess the ability to cross the blood-brain barrier or are otherwise delivered to the brain.

1 - 30 . (canceled) 
     
     
         31 . A method for treatment of a neurodegenerative disease, comprising administering to an individual in need of such treatment a therapeutically effective amount of a compound having the structure: 
       
         
           
           
               
               
           
         
         wherein R is hydrogen, or a C 1  to C 10  alkyl, C 2  to C 10  alkenyl, C 2  to C 10  alkynyl, or C 2  to C 10  alkoxyalkyl group, optionally including heteroatoms; 
         Y 1  and Y 2  are independently C or N; 
         X 4  is hydrogen or halogen; 
         X 3  is CH 2 , CF 2 , S, SO, SO 2 , O, NH, or NR 2 , wherein R 2  is alkyl; and 
         X 2  is halogen, alkyl, halogenated alkyl, alkoxy, halogenated alkoxy, hydroxyalkyl, pyrollyl, optionally substituted aryloxy, alkylamino, dialkylamino, carbamyl, amido, alkylamido, dialkylamido, acylamino, alkylsulfonylamido, trihalomethoxy, trihalocarbon, thioalkyl, SO 2 -alkyl, COO-alkyl, NH 2 , OH, or CN; and 
         X 1  has the formula —X—Y—Z— wherein X, Y and Z are independently C, N, S or O, connected by single or double bonds and with appropriate hydrogen substitution to satisfy valence, or Y may be (CH 2 ) 2 , 
         wherein one of X and Z is bonded at the 5 osition of the aryl ring and the other is bonded to the 4 □position, and wherein the compound is optionally in the form of an acid addition salt; 
         wherein the neurodegenerative disease is selected from the group consisting of complete androgen insensitivity syndrome (CAIS), spinal and bulbar muscular atrophy (SBMA or Kennedy disease), Alzheimer Disease (AD), sporadic frontotemporal dementia with parkinsonism (FTDP), familial FTDP-17 syndromes, Parkinson disease, and Huntington disease. 
       
     
     
         32 . The method of  claim 31 , wherein the compound and the mode of administration are selected such that the compound is delivered to the brain. 
     
     
         33 . The method of  claim 31 , wherein at least one of X, Y and Z is a carbon atom. 
     
     
         34 . The method of  claim 31 , wherein X 1  is —O—(CH 2 ) n —O—, wherein n is 1 or 2. 
     
     
         35 . The method of  claim 31 , wherein X 2  is halogen. 
     
     
         36 . The method of  claim 35 , wherein X 2  is Br or I. 
     
     
         37 . The method of  claim 31 , wherein R is an alkyl group containing a nitrogen heteroatom. 
     
     
         38 . A method for treatment of a neurodegenerative disease, comprising administering to an individual in need of such treatment a therapeutically effective amount of formula: 
       
         
           
           
               
               
           
         
         wherein X 4  is hydrogen or halogen; 
         X 6  is amino; 
         X 3  is C, O, N, or S with hydrogens as necessary to satisfy valence, or CF 2 , SO, SO 2  or NR 3  where R 3  is alkyl; 
         R 1  is hydrogen, a C 1  to C 10  alkyl, alkenyl, alkynyl, or an alkoxyalkyl group, optionally including heteroatoms; 
         R 2  is selected from the group consisting of 
       
       
         
           
           
               
               
           
         
         wherein the squiggly line represents the attachment point to X 3 ; 
         X 2  is halogen, alkyl, halogenated alkyl, alkoxy, halogenated alkoxy, hydroxyalkyl, pyrollyl, optionally substituted aryloxy, alkylamino, dialkylamino, carbamyl, amido, alkylamido dialkylamido, acylamino, alkylsulfonylamido, trihalomethoxy, trihalocarbon, thioalkyl, SO 2 — alkyl, COO-alkyl, NH 2 , OH, or CN; 
         and wherein the compound is optionally in the form of an acid addition salt; 
       
       wherein the neurodegenerative disease is selected from the group consisting of complete androgen insensitivity syndrome (CAIS), spinal and bulbar muscular atrophy (SBMA or Kennedys disease), Alzheimer Disease (AD), sporadic frontotemporal dementia with parkinsonism (FTDP), familial FTDP-17 syndromes, Parkinson disease, and Huntington disease. 
     
     
         39 . The method of  claim 38 , wherein the compound and the mode of administration are selected such that the compound is delivered to the brain. 
     
     
         40 . The method of  claim 38 , wherein X 3  is S. 
     
     
         41 . The method of  claim 38 , wherein X 3  is CH 2 . 
     
     
         42 . The method of  claim 38 , wherein X 2  is I. 
     
     
         43 . The method of  claim 38 , wherein R 1  is an alkyl group containing a nitrogen heteroatom. 
     
     
         44 . The method of  claim 38 , wherein R 1  is selected from the group consisting of 3-isopropylaminopropyl, 3-(isopropyl(methylamino)propyl, 3-(isopropyl(ethylamino)propyl, 3-((2-hydroxyethyl)(isopropyl)amino)propyl, 3-(methyl(prop-2-ynyl)amino)propyl, 3-(allyl(methylamino)propyl, 3-(ethyl(methylamino)propyl, 3-(cyclopropyl(propyl)amino)propyl, 3-(cyclohexyl(2-hydroxyethyl)amino)propyl, 3-(2-methylaziridin-1-yl)propyl, 3-(piperidin-1-yl)propyl, 3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl, 3-morpholinopropyl, 3-(trimethylammonio)propyl, 2-(isopropylamino)ethyl, 2-(isobutylamino)ethyl, 2-(neopentylamino)ethyl, 2-(cyclopropylmethylamino)ethyl, 2-(ethyl(methyl)amino)ethyl, 2-(isobutyl(methyl)amino)ethyl, and 2-(methyl(prop-2-ynyl)amino)ethyl. 
     
     
         45 . A method for treatment of a neurodegenerative disease, comprising administering to an individual in need of such treatment a therapeutically effective amount of formula: 
       
         
           
           
               
               
           
         
         wherein X 4  is hydrogen or halogen; 
         X 6  is amino; 
         X 3  is C, O, N, or S with hydrogens as necessary to satisfy valence, or CF 2 , SO, SO 2  or NR 3  where R 3  is alkyl; 
         R 1  is hydrogen, a C 1  to C 10  alkyl, alkenyl, alkynyl, or an alkoxyalkyl group, optionally including heteroatoms; and 
         R 2  is 
       
       
         
           
           
               
               
           
         
         wherein X 2  is selected from the group consisting of ethylene or 2- propylene, and 
         wherein the compound is optionally in the form of an acid addition salt; 
       
       wherein the neurodegenerative disease is selected from the group consisting of complete androgen insensitivity syndrome (CAIS), spinal and bulbar muscular atrophy (SBMA or Kennedy disease), Alzheimer Disease (AD), sporadic frontotemporal dementia with parkinsonism (FTDP), familial FTDP-17 syndromes, Parkinson  disease, and Huntington disease. 
     
     
         46 . The method of  claim 45 , wherein X 3  is S. 
     
     
         47 . The method of  claim 45 , wherein X 3  is CH 2 . 
     
     
         48 . The method of  claim 45 , wherein X 2  is ethylene. 
     
     
         49 . The method of  claim 45 , wherein R 1  is an alkyl group containing a nitrogen heteroatom. 
     
     
         50 . The method of  claim 45 , wherein R 1  is selected from the group consisting of 3-isopropylaminopropyl, 3-(isopropyl(methylamino)propyl, 3-(isopropyl(ethylamino)propyl, 3-((2-hydroxyethyl)(isopropyl)amino)propyl, 3-(methyl(prop-2-ynyl)amino)propyl, 3-(allyl(methylamino)propyl, 3-(ethyl(methylamino)propyl, 3-(cyclopropyl(propyl)amino)propyl, 3-(cyclohexyl(2-hydroxyethyl)amino)propyl, 3-(2-methylaziridin-1-yl)propyl, 3-(piperidin-1-yl)propyl, 3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl, 3-morpholinopropyl, 3-(trimethylammonio)propyl, 2-(isopropylamino)ethyl, 2-(isobutylamino)ethyl, 2-(neopentylamino)ethyl, 2-(cyclopropylmethylamino)ethyl, 2-(ethyl(methyl)amino)ethyl, 2-(isobutyl(methyl)amino)ethyl, or 2-(methyl(prop-2-ynyl)amino)ethyl.